Long-Term Results of Microwave Thermotherapy for Symptomatic Benign Prostatic Hyperplasia

Tan, Andrew; Nott, Linda; Hardie, W. Robert; Chin, Joseph L.; Denstedt, John D.; Razvi, Hassan

doi:10.1089/end.2005.19.1191

Cited by 16 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The re‐treatment rate (surgery or pharmacotherapy) after high‐energy TUMT is reported to be 3–6% within 1 year 264,265 . Over longer follow‐up periods (up to 5 years), 10–40% of patients required re‐intervention 257,266–268 …”

Section: Surgical Treatment (Surgical Therapy)mentioning

confidence: 99%

JUA clinical guidelines for benign prostatic hyperplasia

et al. 2011

View full text Add to dashboard Cite

Abstract:The Japanese Urological Association has developed Clinical Guidelines for Benign Prostatic Hyperplasia (BPH) for men with suspected BPH. This article is an English translation of the abridged version of the Guidelines. The Guidelines were formulated on the basis of evidence retrieved from the PubMed database between 1995 and 2009, as well as other relevant sources. The target patients of these Guidelines are men with suspected BPH, and the target users are urologists. A mandatory assessment should include a medical history, a physical examination, the completion of symptom and quality of life questionnaires, a urinalysis, a prostate ultrasonography, measurement of serum prostate specific antigen and postvoid residual urine, and uroflowmetry. Optional tests include keeping a bladder diary, the measurement of serum creatinine, and upper urinary tract ultrasonography. Care should be taken to not overlook coexisting diseases such as infections or malignancies that may obscure the diagnosis. Treatment should consist of conservative therapy or the use of medications such as a1-adrenoceptor antagonists, or both. The use of 5a-reductase inhibitors or anticholinergic agents should be considered in patients with an enlarged prostate (>30 mL) or overactive bladder symptoms (Overactive Bladder Symptom Score Ն6), respectively. Surgical intervention is indicated when non-surgical treatments fail to provide sufficient symptomatic relief, and when bladder outlet obstruction is highly suspected.

show abstract

Section: Surgical Treatment (Surgical Therapy)mentioning

confidence: 99%

JUA clinical guidelines for benign prostatic hyperplasia

et al. 2011

View full text Add to dashboard Cite

show abstract

“…A total of 1209 participants were randomised across 11 eligible RCTs reported in 21 papers. 125,126,133,143,159,160,[170][171][172][173][174][219][220][221][222][223][224][225][226][227][228] Three studies took place in the US, 126,159,170 Although all 11 studies gave some details of the ages of participants, three gave only the mean or median age of the participant group as a whole, regardless of which intervention to which they were randomised. 160,171,174 Of the studies reporting IPSS/AUA scores at entry, 475 (74%) participants allocated to TUMT had severe symptoms of BPE and 60 (9%) had moderate symptoms.…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement

Lourenço

Armstrong²,

N’Dow³

et al. 2008

Health Technol Assess

117

View full text Add to dashboard Cite

Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement. Lourenco, T.; Armstrong, N.; N'Dow, J.; Nabi, G.; Deverill, M.; Pickard, R.; Vale, L.; MacLennan, G.; Fraser, C.; McClinton, S.; Wong, S.; Coutts, A.; Mowatt, G.; Grant, A. Published in: Health Technology Assessment Publication date: 2008 Document VersionPublisher's PDF, also known as Version of record Link to publication in Discovery Research Portal Citation for published version (APA):Lourenco, T., Armstrong, N., N'Dow, J., Nabi, G., Deverill, M., Pickard, R., ... Grant, A. (2008). Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement. Health Technology Assessment, 12(35). General rightsCopyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.• You may not further distribute the material or use it for any profit-making activity or commercial gain.• You may freely distribute the URL identifying the publication in the public portal. Take down policyIf you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 12. May. 2018 Health Technology Assessment 2008; Vol. 12: No. 35 Health Technology Assessment NIHR HTA Programme www.hta.ac.uk November 2008 Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement How to obtain copies of this and other HTA Programme reports. An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable CD-ROM is also available (see below).Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our Despatch Agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £3...

show abstract

“…In a study of Tan et al [41] durability of the microwave treatment using the Urowave device was investigated. Thirty-six percent (10/28) of patients needed retreatment in a 5-year period.…”

Section: Transurethral Thermotherapymentioning

confidence: 99%

Nonablative minimally invasive thermal therapies in the treatment of symptomatic benign prostatic hyperplasia

D'ancona¹

2008

Current Opinion in Urology

View full text Add to dashboard Cite

show abstract

Long-Term Results of Microwave Thermotherapy for Symptomatic Benign Prostatic Hyperplasia

Abstract: While improvement in voiding symptoms and Quality of Life scores were maintained without the need for adjuvant treatment in approximately one third of men 5 years after TUMT, a significant number had required salvage therapies for symptom relief.

Cited by 16 publications

References 8 publications

JUA clinical guidelines for benign prostatic hyperplasia

JUA clinical guidelines for benign prostatic hyperplasia

Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement

Nonablative minimally invasive thermal therapies in the treatment of symptomatic benign prostatic hyperplasia

Contact Info

Product

Resources

About